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ABSTRACT
As of now, about 380 medications are implicated in causing respiratory reactions and most common among that is drug-induced interstitial disease. 
Oral, parental as well inhalational drugs are known to cause drug-induced interstitial lung disease. Bleomycin is a chemotherapeutic agent used in 
the treatment of lymphomas, germ cell tumors of the testes. Most common pulmonary toxicity is diffuse alveolar damage with nonspecific interstitial 
pneumonitis being next. We report a case of bleomycin-induced reversible acute interstitial pneumonia in a Hodgkin’s lymphoma patient with 
adriamycin, bleomycin, vinblastine, dacarbazine regimen. Causality assessment was done using Naranjo scale, and probable causal relationship was 
established. Adverse drug reaction was found to be moderately severe and not preventable as per Hartwig’s severity and Thornton’s preventability 
scaling respectively.
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INTRODUCTION
The lungs, with respect to the large surface area, are a potential target 
for many dreaded toxic substances. Specific respiratory reactions are 
noted in lungs as a part of generalized reactions which may be because 
of disease per se or may be because of substances such as drugs, toxins 
and the rest. Lungs are one of the major sites for metabolism of drugs. 
As of now, about 380 medications are implicated in causing respiratory 
reactions and most common among that is drug-induced interstitial 
disease [1]. Other includes involvement of pleura, parenchyma, 
airways, mediastinum, and pulmonary vasculature. Oral, parental as 
well inhalational drugs are known to cause drug-induced interstitial 
lung disease (DILD) [2]. Bleomycin is a chemotherapeutic agent used 
in the treatment of lymphomas, germ cell tumors of the testes. Most 
common pulmonary toxicity is diffuse alveolar damage with nonspecific 
interstitial pneumonitis (NSIP) being next [3]. Hence forth, we report a 
case of bleomycin-induced reversible acute interstitial pneumonia in a 
Hodgkin’s lymphoma patient with adriamycin, bleomycin, vinblastine, 
dacarbazine regimen (ABVD regimen).
CASE REPORT
Informed consent was taken from the patient. A 43-year-old male came 
with complaints of abdominal pain of insidious onset, progressive, 
nonradiating since 1 month duration. It was not associated with altered 
bowels, fever, vomiting, melena, hematemesis, and jaundice. Vitals were 
stable, bowel sounds were normal, and no organomegaly was noted. 
Other system examination was normal. Computed tomography (CT) 
scan of abdomen showed enlarged homogenously enhancing abdominal 
lymph nodes conglomerated in para-aortic, aortocaval, periportal, and 
peripancreatic region (Fig. 1). Diagnostic laparoscopy was done to 
differentiate between abdominal tuberculosis and lymphoma, biopsy 
of para-aortic nodes revealed Hodgkin’s lymphoma of nodular sclerosis 
type. CT scan of chest was taken to rule out metastasis and it was normal 
(Fig. 2). Blood, liver and renal function tests were normal. Hence, the 
patient was started on adriamycin 35 g, bleomycin 14 mg, vinblastine 
8.4 mg, dacarbazine 530 mg (ABVD regimen).
The first cycle was completed, and the patient was fine. Six cycles were 
given every fortnight. On the end of sixth cycle patient complained of 
fever, cough, grade 2 dyspnea, and blue discoloration of nails. Possibility 
of opportunistic infections was ruled out as sputum and respiratory 
culture was negative. Chest X-ray revealed inhomogeneous fluffy 
opacities in right upper and the middle lobe. Hence, CT was taken and 
it showed diffuse ground glass opacification involving both lungs (R>L) 
predominantly in the perihilar region and right middle and lower lobes, 
mild interlobular septal thickening in the basal segments of the right 
lower lobe and medial and lateral segment of right middle lobe, mild 
cystic and cylindrical bronchiectasis changes as described. Possibility 
of diffuse alveolar injury/acute interstitial pneumonia secondary to 
bleomycin drug-induced toxicity (Fig. 3). Follow-up image after 10 days 
revealed features consistent with NSIP pattern confirming the diagnosis 
of drug-induced incidence of ILD.
Hence, the patient was started immediately with levofloxacin 750 mg 
twice daily for 7 days, wysolone 30 mg once daily for 10 days, and tablet 
acyclovir 800 mg thrice daily for 5 days. Patient condition improved 
and repeats CT scan showed minimal bronchiectatic changes with a 
reduction in ground glass opacity signifying reversal of interstitial 
pneumonia (Fig. 4). Later wysolone was slowly tapered over 10 days, 
and bleomycin was removed from the treatment regimen and patient 
continued with his chemotherapy.
DISCUSSION
It is being reported that 2 million cases of adverse drug reactions occur 
every year in the United States, including 1,00,000 deaths. Lungs being 
a major site affected by drugs up to 10% adverse drug reactions result 
in pulmonary toxicity. Literate predicts this number might escalate 
further as DILD is underdiagnosed worldwide and also due to the 
advent of newer medications. ILD worldwide is not clearly known but 
in 2.5-3% drugs have been implicated as the causative factor. Risk factor 
for DILD includes cancer medications, patients treated for rheumatoid 
arthritis, extremes of age, pre-existing lung disease, ethnicity, genetic 
polymorphisms, drug interactions, and radiation.
Most common drugs causing pulmonary toxicity include cytotoxic 
agents, namely, carmustine, cyclophosphamide and bleomycin, 
amiodarone, aspirin, nitrofurantoin, sulfonamides, amphotericin B, 
biological agents, and other miscellaneous drugs. Mechanisms put 
forth in DILD includes injury to alveolar and bronchial epithelial 
due to specificity of some substances, direct toxicity in case of 
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chemotherapeutic agents, due to inadequate removal toxic metabolites, 
disturbance in oxidant/antioxidant hemostasis, due to immune 
medicated antigen - antibody complex deposition and finally due to 
aggregation of amphiphilic compounds in alveolar macrophages [4].
Bleomycin, an antibiotic, isolated from the fungus streptomyces 
verticillus with antitumor activity was discovered by umezewa in 
1966. Bleomycin exerts its antitumor effect by inducing tumor cell 
death, while inhibition of tumor angiogenesis may also be important. 
ABVD and bleomycin, etoposide, cisplatin are common regimens that 
include bleomycin for treatment of Hodgkin’s lymphoma and germ 
cell tumor, Kaposi’s sarcoma, cervical cancer, and squamous cell 
carcinomas of the head and neck are other tumors where bleomycin is 
used. Recently, bleomycin is being used in percutaneous sclerotherapy 
of venous malformations and lymphangiomas. Bleomycin is used in 
combination chemotherapy regimens because of its broad activity and 
low myelotoxicity [5].
Bleomycin, a G2 and M phase cell cycle specific agent, with a molecular 
weight of 1500 has two binding regions, one for iron and other for DNA. 
Cytotoxic activity of bleomycin is mainly because of iron being an 
essential cofactor. Free radical that causes breaks in DNA single and 
double strands are formed when bleomycin binds to iron and oxidizes 
iron molecule finally culminating in cell death. It is said to cause oxidative 
degradation of cellular RNA as well. It has a half-life of 3hrs, and enzyme 
bleomycin hydrolase rapidly inactivates it in the liver and kidneys. Since 
60-70% of drug is eliminated via kidneys careful monitoring and dose 
reduction is required in case of renal dysfunction. Side effects profile 
includes erythema, hyperpigmentation of the skin, discoloration of 
nail bed, hyperkeratosis, chills, hypotension, alopecia, stomatitis, 
myocardial infarction, stroke, and Raynaud’s phenomenon [6].
One of the major limitations of bleomycin therapy is pulmonary 
toxicity. It can occur up to 10% since lungs have very less amounts of 
bleomycin hydrolase required for metabolizing bleomycin into non-
toxic metabolites. Pulmonary syndromes associated with bleomycin 
includes bronchiolitis obliterans organizing pneumonia, eosinophilic 
hypersensitivity, and with most common being interstitial pneumonitis. 
The latter, bleomycin-induced pneumonitis (BIP) has an incidence 
ranging from 0% to 46% with a reasonable estimate of BIP incidence 
being 10% [6]. Mortality ranges up to 10% [7]. Common symptoms 
include dyspnea, clubbing, nonproductive cough, pneumonitis, 
tachypnea, cyanosis with end-inspiratory bibasilar crepitation’s, and 
pleural rubbing.
Pathogenesis involves oxidative damage, deficiency of the bleomycin 
hydrolase, genetic susceptibility, and cytokine-mediated inflammation. 
Membrane instability and inflammation due to fatty acid oxidation 
occurs due to free radical formation, cytokines such as interleukin-1, 
macrophage inflammatory protein-1, platelet-derived growth factor, 
and Transforming growth factor-beta are released from alveolar 
macrophages and this further causes proliferation of fibroblasts leading 
to pulmonary fibrosis. Other postulated mechanisms include loss of 
pulmonary immune tolerance, disruption of balance between collagen 
Fig. 1: Computed tomography scan abdomen with enlarged lymph 
nodes in para-aortic, aortocaval, periportal, and peripancreatic 
region
Fig. 2: Normal chest X-ray before chemotherapy
Fig. 3: Computed tomography chest showing acute interstitial 
pneumonia
Fig. 4: Repeat computed tomography chest showing reversal of 
acute interstitial pneumonia
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deposition and collagenolysis as well fibrin and fibrinolytic system 
resulting in excess collagen and fibrin deposition, respectively [6].
Diagnosis of DILD is based on following criteria [4], (1) a history of 
drug exposure with correct identification of the drug, its dose, and its 
duration of administration, (2) clinical, imaging, and histopathological 
patterns which are consistent with earlier observations with the same 
drug, (3) exclusion of other lung disease, (4) improvement following 
discontinuation of the suspected drug, and (5) recurrence of symptoms 
on rechallenge, but rechallenge can be hazardous.
In our case with the history of exposure to bleomycin other possible 
conditions mimicking DILD was excluded which includes Pneumocystis 
jiroveci as its more common in patients with Hodgkin’s lymphoma 
on chemotherapy and other bacterial, viral infections. CT imaging 
was done to confirm the diagnosis, dechallenge was also done and 
symptoms improved with treatment and repeat CT scan was taken to 
confirm reversal of DILD. Causality assessment was done using Naranjo 





scale, and probable causal relationship was established [8]. Adverse 
drug reaction was found to be moderately severe and not preventable 
as per Hartwig’s severity [8] and Thornton’s preventability scaling [8] 
respectively (Table 1).
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